175 related articles for article (PubMed ID: 30597961)
1. Interaction of ERα and NRF2 Impacts Survival in Ovarian Cancer Patients.
Czogalla B; Kahaly M; Mayr D; Schmoeckel E; Niesler B; Kolben T; Burges A; Mahner S; Jeschke U; Trillsch F
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30597961
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue.
Darb-Esfahani S; Wirtz RM; Sinn BV; Budczies J; Noske A; Weichert W; Faggad A; Scharff S; Sehouli J; Oskay-Ozcelik G; Zamagni C; De Iaco P; Martoni A; Dietel M; Denkert C
Endocr Relat Cancer; 2009 Dec; 16(4):1229-39. PubMed ID: 19675076
[TBL] [Abstract][Full Text] [Related]
3. The aryl hydrocarbon receptor and estrogen receptor alpha differentially modulate nuclear factor erythroid-2-related factor 2 transactivation in MCF-7 breast cancer cells.
Lo R; Matthews J
Toxicol Appl Pharmacol; 2013 Jul; 270(2):139-48. PubMed ID: 23583297
[TBL] [Abstract][Full Text] [Related]
4. Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology.
Czogalla B; Kahaly M; Mayr D; Schmoeckel E; Niesler B; Hester A; Zeder-Göß C; Kolben T; Burges A; Mahner S; Jeschke U; Trillsch F
Cancer Manag Res; 2019; 11():7673-7684. PubMed ID: 31616183
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.
Chan KKL; Siu MKY; Jiang YX; Wang JJ; Wang Y; Leung THY; Liu SS; Cheung ANY; Ngan HYS
BMC Cancer; 2017 Aug; 17(1):606. PubMed ID: 28859612
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival.
Halon A; Materna V; Drag-Zalesinska M; Nowak-Markwitz E; Gansukh T; Donizy P; Spaczynski M; Zabel M; Dietel M; Lage H; Surowiak P
Pathol Oncol Res; 2011 Sep; 17(3):511-8. PubMed ID: 21207255
[TBL] [Abstract][Full Text] [Related]
7. Expression Patterns of Nrf2 and Keap1 in Ovarian Cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival.
Cho HY; Kim K; Kim YB; Kim H; No JH
Int J Gynecol Cancer; 2017 Mar; 27(3):412-419. PubMed ID: 28129239
[TBL] [Abstract][Full Text] [Related]
8. Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression.
Wu J; Zhang L; Li H; Wu S; Liu Z
Biochem Biophys Res Commun; 2019 Oct; 518(4):698-705. PubMed ID: 31472965
[TBL] [Abstract][Full Text] [Related]
9. Estrogen-independent role of ERα in ovarian cancer progression induced by leptin/Ob-Rb axis.
Ghasemi A; Saeidi J; Mohtashami M; Hashemy SI
Mol Cell Biochem; 2019 Aug; 458(1-2):207-217. PubMed ID: 31077012
[TBL] [Abstract][Full Text] [Related]
10. Dietary tocopherols inhibit cell proliferation, regulate expression of ERα, PPARγ, and Nrf2, and decrease serum inflammatory markers during the development of mammary hyperplasia.
Smolarek AK; So JY; Thomas PE; Lee HJ; Paul S; Dombrowski A; Wang CX; Saw CL; Khor TO; Kong AN; Reuhl K; Lee MJ; Yang CS; Suh N
Mol Carcinog; 2013 Jul; 52(7):514-25. PubMed ID: 22389237
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer.
De Stefano I; Zannoni GF; Prisco MG; Fagotti A; Tortorella L; Vizzielli G; Mencaglia L; Scambia G; Gallo D
Gynecol Oncol; 2011 Sep; 122(3):573-9. PubMed ID: 21665249
[TBL] [Abstract][Full Text] [Related]
12. Repression of cancer protective genes by 17beta-estradiol: ligand-dependent interaction between human Nrf2 and estrogen receptor alpha.
Ansell PJ; Lo SC; Newton LG; Espinosa-Nicholas C; Zhang DD; Liu JH; Hannink M; Lubahn DB
Mol Cell Endocrinol; 2005 Nov; 243(1-2):27-34. PubMed ID: 16198475
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients.
Kirn V; Shi R; Heublein S; Knabl J; Guenthner-Biller M; Andergassen U; Fridrich C; Malter W; Harder J; Friese K; Mayr D; Jeschke U
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1681-7. PubMed ID: 24908329
[TBL] [Abstract][Full Text] [Related]
14. Expression and clinical significance of estrogen-regulated long non-coding RNAs in estrogen receptor α-positive ovarian cancer progression.
Qiu JJ; Ye LC; Ding JX; Feng WW; Jin HY; Zhang Y; Li Q; Hua KQ
Oncol Rep; 2014 Apr; 31(4):1613-22. PubMed ID: 24481591
[TBL] [Abstract][Full Text] [Related]
15. microRNA-206 overexpression inhibits cellular proliferation and invasion of estrogen receptor α-positive ovarian cancer cells.
Li S; Li Y; Wen Z; Kong F; Guan X; Liu W
Mol Med Rep; 2014 May; 9(5):1703-8. PubMed ID: 24604205
[TBL] [Abstract][Full Text] [Related]
16. High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling.
Kim D; Choi BH; Ryoo IG; Kwak MK
Cell Death Dis; 2018 Aug; 9(9):896. PubMed ID: 30166520
[TBL] [Abstract][Full Text] [Related]
17. The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer.
Tian L; Peng Y; Yang K; Cao J; Du X; Liang Z; Shi J; Zhang J
Cell Commun Signal; 2022 Nov; 20(1):178. PubMed ID: 36376959
[TBL] [Abstract][Full Text] [Related]
18. Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium.
Aust S; Bachmayr-Heyda A; Pateisky P; Tong D; Darb-Esfahani S; Denkert C; Chekerov R; Sehouli J; Mahner S; Van Gorp T; Vergote I; Speiser P; Horvat R; Zeillinger R; Pils D
Mol Cancer; 2012 Sep; 11():69. PubMed ID: 22978347
[TBL] [Abstract][Full Text] [Related]
19. The expression and correlation between the transcription factor FOXP1 and estrogen receptors in epithelial ovarian cancer.
Hu Z; Zhu L; Tan M; Cai M; Deng L; Yu G; Liu D; Liu J; Lin B
Biochimie; 2015 Feb; 109():42-8. PubMed ID: 25500588
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
